Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Reviews Endocrinology

• Publication date

  2025-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41574-025-01170-4PMID 40935880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.

  2024cited by this paper
• Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial

  2024cited by this paper
• Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy

  2024cited by this paper
• Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation

  2024cited by this paper
• Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta‐analysis

  2024cited by this paper
• 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association

  2024cited by this paper
• The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.

  2024cited by this paper
• Endothelin receptor antagonists in chronic kidney disease

  2024cited by this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis

  2024cited by this paper
• Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels

  2024cited by this paper
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

  2024cited by this paper
• Cardiovascular outcome with SGLT2i and GLP1RA.

  2024cited by this paper
• Current status and future trends of the global burden of MASLD.

  2024cited by this paper
• Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns

  2024cited by this paper
• Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.

  2024cited by this paper
• Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression

  2024cited by this paper
• Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study

  2024cited by this paper
• The Effect of Sodium-Glucose Transporter 2 Inhibitors on Stroke in Patients With Type 2 Diabetes: A Meta-analysis.

  2024cited by this paper
• The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium–Glucose Transporter 2 Inhibitors

  2024cited by this paper
• Empagliflozin after Acute Myocardial Infarction.

  2024cited by this paper
• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

  2024cited by this paper
• Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study

  2023cited by this paper
• SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism

  2023influential reference
• Metabolic Communication by SGLT2 Inhibition

  2023cited by this paper
• Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2

  2023cited by this paper
• Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

  2023cited by this paper
• SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes.

  2023cited by this paper
• Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial

  2023cited by this paper
• Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

  2023cited by this paper
• SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model.

  2023cited by this paper
• Novel Perspectives Regarding the Physiologic Mechanisms by which Gliflozins Induce Reticulocytosis and Erythrocytosis.

  2023cited by this paper
• Association of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) with Cardiac Arrhythmias: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials

  2023cited by this paper
• Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

  2023cited by this paper
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.

  2023cited by this paper
• Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial

  2023cited by this paper
• Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2023cited by this paper
• Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease.

  2023cited by this paper
• SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.

  2022cited by this paper
• Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

  2022cited by this paper
• Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis

  2022cited by this paper
• Association of Sodium-Glucose Cotransporter-2 Inhibitors with Time to Dementia: A Population-Based Cohort Study.

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022cited by this paper
• Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II

  2022cited by this paper
• Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure

  2022cited by this paper
• Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

  2022cited by this paper
• Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

  2022cited by this paper
• Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

  2022cited by this paper
• Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.

  2022cited by this paper
• Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

  2022cited by this paper
• Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

  2022cited by this paper
• The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis

  2022cited by this paper
• Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

  2022influential reference
• SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF‐2α signaling pathway in arrhythmogenic cardiomyopathy

  2022cited by this paper
• SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients

  2022cited by this paper
• The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial

  2022cited by this paper
• Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.

  2022cited by this paper
• Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.

  2022influential reference
• Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells

  2022influential reference
• Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

  2021cited by this paper
• Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway

  2021cited by this paper
• Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta‐analysis

  2021cited by this paper
• Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects

  2021influential reference
• The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

  2021cited by this paper
• Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

  2021influential reference
• Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation

  2021cited by this paper
• Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis

  2021cited by this paper
• Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin.

  2021cited by this paper
• Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin

  2021cited by this paper
• Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease

  2021cited by this paper
• Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure

  2021cited by this paper
• Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus

  2021cited by this paper
• Cardiac Energy Metabolism in Heart Failure

  2021cited by this paper
• Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2021influential reference
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2021influential reference
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

  2020cited by this paper
• Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials

  2020cited by this paper
• Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

  2020cited by this paper
• Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney

  2020cited by this paper
• Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.

  2020cited by this paper
• Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

  2020cited by this paper
• SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

  2020cited by this paper
• Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity

  2020cited by this paper
• Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes

  2020cited by this paper
• Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.

  2020influential reference
• Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice

  2020cited by this paper
• Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities.

  2020cited by this paper
• Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics

  2020cited by this paper
• Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice

  2020cited by this paper
• Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.

  2020cited by this paper
• Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea

  2020cited by this paper
• Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR and restores euvolemia in nondiabetic rats with induced heart failure

  2020cited by this paper
• SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.

  2020cited by this paper
• Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling

  2020cited by this paper
• Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes

  2020cited by this paper
• A role for the tubular Na+-H+-exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

  2020cited by this paper
• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020influential reference
• Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

  2020influential reference
• Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

  2020cited by this paper
• Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

  2020cited by this paper

• Mechanistic insights into the role of salicin in mitigating oxidative and inflammatory pathways of diabetic complications

  2026cites this paper
• Amino acid infusion and SGLT2 inhibitors for kidney protection: Plausible adverse impact of tubular transport load on renal tissue oxygenation.

  2026cites this paper
• Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition

  2026cites this paper
• Off-Label Dapagliflozin After Atrial Fibrillation Ablation: A Reasonable Intervention or Overstretching the Evidence?

  2026cites this paper
• Immunometabolism Reframes Alzheimer’s Disease: From Systemic Dysmetabolism to Glial Rewiring

  2026cites this paper
• Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study.

  2025cites this paper
• Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact

  2025cites this paper
• Obesity phenotypes and atherogenic dyslipidemias

  2025influential citation
• Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications.

  2025cites this paper
• SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration

  2025cites this paper